Akari Therapeutics PLC (ADR) (AKTX) was Initiated by Chardan Capital Markets to “Sell” and the brokerage firm has set the Price Target at $5. Chardan Capital Markets advised their investors in a research report released on Jul 11, 2016.
Many Wall Street Analysts have commented on Akari Therapeutics PLC (ADR). Chardan Capital Markets Initiated Akari Therapeutics PLC (ADR) on Jul 11, 2016 to “Sell”, Price Target of the shares are set at $5.
In a different news, on Sep 22, 2015, Mark S Cohen (director) purchased 1,055,600 shares at $0.19 per share price.
Akari Therapeutics Plc formerly Celsus Therapeutics plc is a United Kingdom-based development-stage biopharmaceutical company. The Company is focused on the development and commercialization of anti-complement and anti-inflammatory molecules as life-transforming treatments for a range of orphan autoimmune and inflammatory diseases. Its lead drug Coversin is a second-generation complement inhibitor that acts on complement component-C5 preventing release of C5a and formation of C5b-9 (also known as the membrane attack complex). C5 inhibition is available in rare autoimmune diseases related to dysregulation of the complement component of the immune system including paroxysmal nocturnal hemoglobinuria (PNH) Atypical Hemolytic Uremic Syndrome (aHUS) and Guillain Barre Syndrome (GBS). Coversin is a recombinant small protein (16740 Da) derived from a protein discovered in the saliva of the Ornithodoros moubata tick. Coversin is in Phase II clinical trials in PNH aHUS and GBS.